This study investigates the use of an investigational medication in combination with hypofractionated radiation therapy for treating locally advanced pancreatic cancer. The purpose is to explore the safety and effectiveness of this combination in patients whose cancer has spread to nearby tissues or lymph nodes.
The study evaluates how well the investigational medication works with radiation therapy. It focuses on understanding the safety and tolerability of this combination and how it affects progression-free survival compared to radiation therapy alone.
- Who can participate: Adults aged 18 or older with confirmed locally advanced pancreatic adenocarcinoma, who have completed a specific chemotherapy regimen, may participate. Participants should have measurable disease and meet certain health criteria.
- Study details: Participants will receive either the investigational medication or a placebo along with radiation therapy. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand